(NASDAQ: KROS) Keros Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.96%.
Keros Therapeutics's earnings in 2026 is $64,449,000.On average, 12 Wall Street analysts forecast KROS's earnings for 2026 to be -$100,650,752, with the lowest KROS earnings forecast at -$146,895,198, and the highest KROS earnings forecast at -$23,672,136. On average, 11 Wall Street analysts forecast KROS's earnings for 2027 to be -$110,357,242, with the lowest KROS earnings forecast at -$170,482,029, and the highest KROS earnings forecast at -$23,032,348.
In 2028, KROS is forecast to generate -$81,054,977 in earnings, with the lowest earnings forecast at -$102,110,077 and the highest earnings forecast at -$34,548,522.